Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Sarah Anne Bird
Observed names:
S. Bird,
Sarah A. Bird,
Sarah Bird
Institutions:
Royal Marsden NHS Foundation Trust,
Institute of Cancer Research,
Royal Marsden Hospital
Observed institutions:
National Health Service,
Royal Marsden NHS Foundation Trust,
Institute of Cancer Research,
Royal Free London NHS Foundation Trust,
Institute of Cancer Research,
Royal Marsden Hospital,
North Middlesex University Hospital NHS Trust,
North Middlesex Hospital
show all 8
ORCID:
0000-0001-8080-0937
Observed ORCID:
0000-0001-8080-0937
OpenAlex ID:
A5014589663
Works
26
Awards
1
Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma
2021
·
Sarah Bird
, Aikaterini Panopoulou
, et al.
·
The Lancet Haematology
·
133
PDF
Multiple myeloma: an overview of management
2019
·
Sarah Anne Bird
, Kevin Boyd
·
Palliative Care and Social Practice
·
129
IMiD Resistance in Multiple Myeloma: Current Understanding of the Underpinning Biology and Clinical Impact
2023
·
Sarah Anne Bird
, Charlotte Pawlyn
·
Blood
·
77
PDF
Sex Differences in Multiple Myeloma Biology but not Clinical Outcomes: Results from 3894 Patients in the Myeloma XI Trial
2021
·
Sarah Bird
, David Cairns
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
·
69
PDF
The signs, symptoms and help-seeking experiences of neutropenic sepsis patients before they reach hospital: a qualitative study
2015
·
Rachel T. Clarke
, Sarah Bird
, et al.
·
Supportive Care in Cancer
·
33
Fabry disease and incidence of cancer
2017
·
Sarah Bird
, Efthymios Hadjimichael
, et al.
·
Orphanet Journal of Rare Diseases
·
25
PDF
Evaluating the impact of CRBN mutations on response to immunomodulatory drugs and novel cereblon E3 ligase modulators in myeloma
2025
·
Yakinthi Chrisochoidou
, Andrea Scarpino
, et al.
·
Blood
·
21
A real‐world study of panobinostat, weekly bortezomib and dexamethasone in a very heavily pretreated population of multiple‐myeloma patients
2020
·
Sarah Bird
, Charlotte Pawlyn
, et al.
·
British Journal of Haematology
·
11
Ixazomib, lenalidomide, and dexamethasone is effective and well tolerated in multiply relapsed (≥2nd relapse) refractory myeloma: a multicenter real world UK experience
2020
·
Nadjoua Maouche
, Bhuvan Kishore
, et al.
·
Leukemia & lymphoma/Leukemia and lymphoma
·
8
Investigating the Functional Impact of CRBN Mutations on Response to IMiD/Celmod Agents in Myeloma
2023
·
Yakinthi Chrisochoidou
, Yann-Vai LeBihan
, et al.
·
Blood
·
7
Sex Differences in Multiple Myeloma Biology and Clinical Outcomes: Results from 3894 Patients in the Myeloma XI Trial
2019
·
Sarah Anne Bird
, David Cairns
, et al.
·
Blood
·
7
Multiomics Analysis of IMiD/CELMoD Resistant Multiple Myeloma Models Uncovers Novel and Targetable Vulnerabilities in the SREBP Lipid Synthesis Pathway
2022
·
Sarah A. Bird
, Amy Barber
, et al.
·
Blood
·
6
EZH2 Inhibition Overcomes Immunomodulatory Drug (IMiD) Resistance in Multiple Myeloma Cell Lines in a Cereblon Pathway Dependent Manner
2023
·
Yigen Li
, Amy Barber
, et al.
·
Blood
·
5
Maintenance Strategies Post-Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma
2020
·
Sarah A. Bird
, Graham H. Jackson
, et al.
·
Clinical Hematology International
·
5
PDF
EZH2 inhibition overcomes immunomodulatory drug resistance in multiple myeloma via a cereblon-dependent pathway
2026
·
Yigen Li
, Amy Wilson
, et al.
·
Haematologica
·
3
IMiDs and Celmods Enhance Antigen Presentation Via MHC Class 1 - a Potential Novel Immunostimulatory Effect
2024
·
Shannon Martin
, Yakinthi Chrisochoidou
, et al.
·
Blood
·
2
PDF
P-144: Response to SARS-CoV-2 vaccination in patients with Multiple Myeloma using a 12-week spaced dosing strategy
2021
·
Sarah Bird
, Aikaterini Panopoulou
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
·
2
PDF
IMiD/CELMoD resistance in myeloma is associated with changes in lipid metabolism that may be targetable
2026
·
Sarah A. Bird
, Marco P. Licciardello
, et al.
·
Blood Neoplasia
·
1
P-179 Altered lipid metabolism in IMiD/CELMoD resistant multiple myeloma confers novel and targetable vulnerabilities
2023
·
Sarah Bird
, Yitao Xu
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
·
1
MM-146: A Real-World Study of Bendamustine Therapy in a Very Heavily Pre-Treated Population of Multiple Myeloma Patients
2021
·
Sarah Bird
, Akaterina Panopoulou
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
·
1
Specialist palliative care (SPC) in haematological malignancy: Establishing practices in a UK tertiary cancer centre (TCC)
2019
·
E. Kedgley
, M. Nanda Kumar
, et al.
·
Annals of Oncology
·
1
SETD2 is a novel and druggable dependency in IMiD/CELMoD resistant multiple myeloma models
2026
·
Sarah A. Bird
, Marco P. Licciardello
, et al.
·
Blood Cancer Journal
PDF
Abstract 3879: SETD2 is a novel and druggable dependency in IMiD/CELMoD resistant multiple myeloma models
2023
·
Sarah Anne Bird
, Marco Licciardello
, et al.
·
Cancer Research
Poster: MM-146: A Real-World Study of Bendamustine Therapy in a Very Heavily Pre-Treated Population of Multiple Myeloma Patients
2021
·
Sarah Bird
, Akaterina Panopoulou
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
MM-296: A Real-World Study of Panobinostat, Weekly Bortezomib, and Dexamethasone in a Very Heavily Pre-Treated Population of Multiple Myeloma Patients
2020
·
Sarah Bird
, Charlotte Pawlyn
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
Show more works
View as search
Works count:
26
Citation count:
547
H-index:
8
I10-index:
8
Year
Topic
Type